A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early

Launched by TUFTS MEDICAL CENTER · Apr 13, 2016

Keywords

ClinConnect Summary

In this trial up to 200 patients with either λ light chain (LC) monoclonal gammopathy of undetermined significance (MGUS) or λ LC smoldering multiple myeloma (SMM) with a κ::λ LC ratio \< 0.26 and whose λ minus κ LC difference (dFLC) is greater than 23 mg/L will be recruited. Heavy chain type will not affect patient eligibility as long as the involved LC is λ type.

Patients may learn about the trial through internet advertisements and contact the data manager to receive the study's enrollment documents. Patient recruitment will be open to all eligible patient within the United States. Info...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • MGUS and SMM patients with λ LC involvement with dFLC \> 23 mg/L and κ:: λ free LC ratios \< 0.26. Subjects must be able to share their medical records and ship us bone marrow and blood samples.
• Exclusion Criteria:
• • MGUS and SMM patients with light chains that do not meet the inclusion criteria as well as patients with κ LC involvement or active myeloma will not be included. And patients who are unable to send us blood and marrow for any reason will not be eligible.

Trial Officials